An interventional study of Adults EXPLORER in Neuromuscular Disorders, sponsored by MarsiBionics. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-04.
Sponsored by MarsiBionics · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Neuromuscular Diseases with a site in Spain — 5 open to participants now, 10 under way, 3 of them phase 3. Neuromuscular Diseases · Spain.
Among the 35 studies in Neuromuscular Diseases with a site in Spain, this one is the 28th largest by planned enrollment of the 30 interventional ones that give a count, is one of 6 that started in 2025, is one of 14 with no phase, and was the 29th registered.
361 studies on the registry are indexed under Neuromuscular Diseases; 96 are open to participants now.
Browse Neuromuscular Diseases studies →5 of the 35 studies in Neuromuscular Diseases with a site in Spain are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in Spain, Australia, Belgium and 7 more countries
Ages 7–16 · Men only
AstraZeneca · Sites in Spain, United States, Canada and 7 more countries
Ages 18–70
Vertex Pharmaceuticals Incorporated · Sites in Spain, United States, Australia and 5 more countries
Ages 18+
MarsiBionics · Sites in Spain, Mexico
Ages 2–17 · Healthy volunteers
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 69 Neuromuscular Diseases studies recruiting now, 39 (57%) set no upper age limit and 22 (32%) stop at 75 or younger; 35 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 9
First in 2012; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 7 is below the median of 30 across 204 interventional studies indexed under Neuromuscular Diseases.
Median enrollment 55 across the 30 interventional studies, 48 across the 5 observational. Of the 21 that completed or were terminated, 9 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 35 have an industry lead sponsor. The 10 most frequent:
MarsiBionics is the lead sponsor of 14 studies on the registry; 3 are open to participants now.
MarsiBionics has 6 studies filed under Neuromuscular Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in Neuromuscular Diseases with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07745712ABLE Human Motion S.L.Clinical Investigation to Validate the Safety and Performance of the ABLE Kids Device in Pediatric Patients With Neurological Gait Disorders in a Clinical Setting | 2026-12-31 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT07287189Satellos Bioscience, Inc.Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients | 2027-03-31 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 35 studies in Neuromuscular Diseases with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Neurodevelopmental disorders frequently result in abnormal development of the Central Nervous System (CNS), often leading to motor impairments such as difficulty in standing and walking. EXPLORER is a robotic exoskeleton for gait rehabilitation, specifically designed for adults aged 18 to 85 with motor disabilities.The aim of this study is to evaluate the safety and usability of the EXPLORER for adults with motor disability.
Neurodevelopmental disorders frequently result in abnormal development of the Central Nervous System (CNS), often leading to motor impairments such as difficulty in standing and walking. EXPLORER is a robotic exoskeleton for gait rehabilitation, specifically designed for adults aged 18 to 85 with motor disabilities. The aim of this study is to evaluate the safety and usability of the EXPLORER for adults with motor disability.
This study will involve testing the gait-assistance exoskeleton in healthy patients during the first phase, and in patients with stroke (ACV), acquired brain injury (DCA), multiple sclerosis (EM), and muscular dystrophy (LM) during the second phase. The study will consist of two phases:
Phase 1: One visit with the device in healthy patients to assess the initial safety and comfort of the device.
Phase 2: A screening visit (S0) followed by two treatment visits with the device (V1-V2) in patients with ACV, DCA, EM, and LM to determine the effectiveness of the device in treating motor impairments caused by these conditions.
The goal of the study is to evaluate the safety and usability of the device in patients with ACV, DCA, EM, and LM, in order to identify potential benefits in improving gait, muscle strength, and overall functionality in this patient group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion criteria related to the device characteristics:
Inclusion criteria related to the study:
Exclusion Criteria:
Two sessions with the robotic gait device in patients with neuromuscular diseases.
Device: Adults EXPLORER
Two sessions with the robotic gait device in patients with neuromuscular diseases.
Serious Adverse Events
Occurrence of any serious adverse event to the participant or the caregiver
Time frame: Through study completion, an average of 1 month
Falls prevalence
Number of falling events occurred from the participant or caregiver
Time frame: Through study completion, an average of 1 month
Heart Rate
Beats per minute
Time frame: Through study completion, an average of 1 month
Skin integrity
Occurrence of any injury of the skin in the areas of contact and produced by the use of the device
Time frame: Through study completion, an average of 1 month
Device usage time
Time using the device
Time frame: Through study completion, an average of 1 month
Level of Spasticity
Evaluation of spasticity with Modified Ahsworth Scale
Time frame: Through study completion, an average of 1 month
Level of fatigue
Fatigue of both the participant and the therapist, Measured with the Borg scale
Time frame: Through study completion, an average of 1 month
Donning and doffing time
Time to don and doff the device to each participant
Time frame: Through study completion, an average of 1 month
Level of assistance a participant requires for walking
Measure with FAC scale
Time frame: Through study completion, an average of 1 month
Walking ability of individuals with spinal cord injuries
Measure with WISCII (SCI) scale
Time frame: Through study completion, an average of 1 month
TUG
The Time Up and Go test is used to assess a participant's mobility and balance
Time frame: Through study completion, an average of 1 month
10MWT
The 10-Meter Walk Test is used to assess walking speed by measuring the time taken to walk 10 meters at a comfortable pace.
Time frame: Through study completion, an average of 1 month
QUEST 2.0
Using the Quebec User Evaluation of Satisfaction with Assistive Technology questionnaire administered to the participants' caregivers at the end of the intervention. The QUEST 2.0 scale has 12 items. Each item is rated on a 5-point Likert scale
Time frame: at the end of the intervention, an average of 1 month
Blood Pressure
Measure in mmHg
Time frame: Through study completion, an average of 1 month
Oxygen Saturation
It analyzes this absorption and calculates the SpO₂
Time frame: Through study completion, an average of 1 month
Start is estimated for Jul 2025; primary completion for Jul 2025, 0 months later.
Of 84 interventional studies with no phase under Neuromuscular Diseases, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 0 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MarsiBionics